CYP2C19 and major depressive disorder: Indeed, the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, which focuses on major depression and anxiety disorders, suggests that CYP2C19 genotyping could be used to identify poor metabolizers of sertraline, citalopram, or escitalopram at risk of side effects due to high plasma concentrations, as well as ultra-rapid metabolizer at risk of treatment failure due to low plasma concentrations [6].